Navigation Links
Celebrex inhibited the burden of skin cancer in high-risk patients
Date:1/4/2010

PHILADELPHIA People with the heritable disorder of the skin called Gorlin syndrome who are genetically predisposed to develop basal cell carcinoma of the skin may have a new chemoprevention therapy on the horizon.

According to results of a placebo-controlled, randomized, double-blind, Phase II study, the use of celecoxib was effective in inhibiting the development of basal cell carcinomas in a relatively rare group of patients who are highly susceptible to carcinoma. These findings are published in the January issue of Cancer Prevention Research, a journal of the American Association for Cancer Research.

Celecoxib, sold under the brand name of Celebrex by Pfizer Inc., is a non-steroidal anti-inflammatory drug (NSAID). Patients with Gorlin syndrome typically develop hundreds or even thousands of basal cell carcinomas in their lifetime.

Ervin H. Epstein Jr., M.D., senior scientist at the Children's Hospital of Oakland Research Institute, Oakland, Calif., said the goal of this study was to reduce the number of basal cell carcinomas in patients with this rare disorder who are most at risk for this form of cancer.

"The underlying idea is if we can find something in these high-risk patients that could be translatable to the 'normal' population, then we could ultimately use that form of chemoprevention to reduce the numbers of skin cancer in all people," he said.

Epstein and colleagues randomized 60 patients with basal cell carcinoma to receive either 200 mg of oral celecoxib two times a day or placebo. After about two years, patients who received placebo had a 50 percent increase in basal cell carcinoma per year compared with a 20 percent increase among those who received celecoxib.

"We found some beneficial effect of preventing tumors in patients treated with the NSAID," Epstein said.

Furthermore, there was no difference in the rate or severity of side effects between patients in either g
'/>"/>

Contact: Tara Yates
tara.yates@aacr.org
267-646-0558
American Association for Cancer Research
Source:Eurekalert  

Page: 1 2

Related biology news :

1. KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex
2. Poor Americans in the United States suffer hidden burden of parasitic and other neglected diseases
3. NTDs burden in Latin America and the Caribbean may exceed that of HIV/AIDS, TB and malaria
4. Fighting the burden of mental disorders
5. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
6. A study by the MUHC and McGill University opens a new door to understanding cancer
7. ESF EURYI award winner aims to stop cancer cells reading their own DNA
8. Protein chatter linked to cancer activation
9. Newly created cancer stem cells could aid breast cancer research
10. Western diet linked to increased risk of colon cancer recurrence
11. Obesity and lack of exercise could enhance the risk of pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Celebrex inhibited the burden of skin cancer in high-risk patients
(Date:8/20/2014)... and plastic bags could one day be made out ... scientists are now reporting. The novel process they developed ... with its agricultural and plastic waste problems, appear in ... Ilker S. Bayer and colleagues at the Italian Institute ... growing. In 2012, its production reached 288 million tons ...
(Date:8/20/2014)... light and its energy is finally utilized for ... devices, mostly build from silicon based semiconductors, also ... for the development of cheaper and renewable photovoltaics ... membrane protein complexes of photosynthesis. Prof. Dr. Matthias ... thermophilic cyanobacteria that live in a hot spring ...
(Date:8/19/2014)... systems be used in supermarkets to encourage healthier spending ... to answer that very question by tracking the purchasing ... Stars System to rate the nutritional value of foods ... Brand Lab,s David Just, PhD, and Brian Wansink PhD, ... records of over 150 Hannaford Supermarkets in the Northeastern ...
Breaking Biology News(10 mins):A semi-artificial leaf faster than 'natural' photosynthesis 2
... Inflammation of gum tissues periodontitis is one of ... susceptible to diseases of the circulatory system, rheumatoid arthritis, ... of Jan Potempa, PhD, DSc, professor and academic scholar, ... School of Dentistry, have helped change scientific thinking about ...
... Ore. -- A constellation of defective proteins suspected in causing ... DNA could be the link scientists need to prove a ... broad range of ovarian cancer patients, an Oregon Health & ... results, published this week in PLoS ONE , have ...
... DC - On January 18, 2012, Dr. Peter ... National Homeland Security Research Center in the Office ... Protection Agency, will lead a session titled "National ... national resilience to bioterrorism threats involves maximizing advanced ...
Cached Biology News:UofL researcher earns the Foundation for Polish Science Prize 2Faulty proteins may prove significant in identifying new treatments for ovarian cancer 2
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... is being held on October 29-30 in San Francisco, ... industry, academic and government researchers and clinicians focused on ... space. , In the twelve years since the ... therapies have been introduced with pharmacogenetic information in the ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... Cellgen Diagnostics today launched ... a corporate lab for its genetic-based medical testing ... a critical component in the move from today’s ... of personalized medicine – a more predictive, preventive, ... contributions will support Cellgen’s intent to develop the ...
(Date:8/19/2014)... BURNIE, Md. , Aug. 19, 2014 ... clinical research industry, recently announced the formation of the ... pleased to announce the addition of Dr. William ... Photo - http://photos.prnewswire.com/prnh/20140818/136957 The ... across a variety of therapeutic areas and set strategic ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3
... , MONTRÉAL, Jan. 19 /PRNewswire-FirstCall/ - ... established a Special Committee of independent Board members to explore ... a sale of the Company or the sale of all ... be working with management and external consultants to expeditiously make ...
... ... of integration, functionality, innovation, manageability, performance and value provided to end users. , ... (PRWEB) January 19, 2010 ... Silver Award for Virtualization Management. This annual award identifies the companies ...
... NEW HAVEN, Conn. , Jan. 19 ... Richard J. Carroll to the newly created position ... HistoRx over 20 years of sales, marketing, research, and general ... Before joining HistoRx in 2009, he was Vice President of ...
Cached Biology Technology:ConjuChem to evaluate strategic alternatives 2VKernel's Optimization Pack Wins Award In SearchServerVirtualization.Com's 2009 Products of the Year Survey 2HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 2HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 3